Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors Resistance

NCT06118645 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT06118645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06118645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors Resistance
Lead sponsor
China Medical University, China
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2023
Completion date
August 1, 2026
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma